S&P DJI Announces March 2024 Quarterly Rebalance
Filed with ASX · · 8 pages · English
Earlier from Racura Oncology
- Race Receives $4.0m R&D Tax Refund for Financial Year 2023
- December 2023 Preclinical & Clinical Program Update
- Bonus Options Prospectus
- Updated Strategy and Investor Presentation
- Dr Daniel Tillett appointed CEO of Race Oncology
Later from Racura Oncology
- Bisantrene shows potent anticancer activity in AML models
- RC220 cGMP Manufacturing Complete
- Quarterly Activity Report & Appendix 4C
- Bisantrene with Decitabine Enhances Cancer Cell Killing
- US FDA Orphan Drug Designation Awarded to RC220 Bisantrene
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology